肾
肾脏疾病
医学
体内
病理
靶向给药
离体
活体显微镜检查
免疫系统
全身给药
药理学
药品
内科学
免疫学
生物
生物技术
微循环
作者
Ryan M. Williams,Janki Shah,Helen S. Tian,Xi Chen,Frédéric Geissmann,Edgar A. Jaimes,Daniel A. Heller
出处
期刊:Hypertension
[Lippincott Williams & Wilkins]
日期:2017-11-13
卷期号:71 (1): 87-94
被引量:135
标识
DOI:10.1161/hypertensionaha.117.09843
摘要
Direct targeting to the kidneys is a promising strategy to improve drug therapeutic index for the treatment of kidney diseases. We sought to investigate the renal selectivity and safety of kidney-targeted mesoscale nanoparticle technology. We found that direct intravenous administration of these particles resulted in 26-fold renal selectivity and localized negligibly in the liver or other organs. The nanoparticles targeted the renal proximal tubular epithelial cells, as evidenced by intravital microscopy and ex vivo imaging. Mice treated with the nanoparticles exhibited no negative systemic consequences, immune reaction, liver impairment, or renal impairment. The localization of material selectively to the renal tubules is uncommon, and this work portends the development of renal-targeted drugs for the treatment of kidney diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI